News & Updates

Children with atopic dermatitis (AD) are at greater risk of impaired linear growth, but treatment with dupilumab may lessen the risk, suggests a study.

Outcomes are similar among patients with moderate-to-severe psoriasis who continued treatment with ustekinumab and those who switched to BAT2206, a drug being developed as a biosimilar of ustekinumab, according to a study.

Treatment with rifaximin appears to provide no benefits in terms of 12-month survival or incidence of complications of cirrhosis in patients with severe cirrhosis and low ascitic fluid protein levels, a recent study has shown.

A trend toward increased continuous use of tumour necrosis factor inhibitors has been observed throughout gestation, which suggests growing confidence in the safety and effectiveness of this medication during pregnancy, reveals a study.

A recent study has noted a temporary increase in antimicrobial use following initiation of tumour necrosis factor inhibitor (TNFi) treatment, with no significant risk in serious infections, among patients with psoriatic arthritis (PsA).

A retrospective study from Italy shows an association between nirsevimab prophylaxis and a lower risk of respiratory syncytial virus (RSV) hospitalizations and a milder disease course.

The use of oral anticoagulants (OACs) with NSAIDs results in clinical outcomes like those of OAC monotherapy, a study has shown.